LY3214996 proves effective in delaying or reversing resistance to BRAF and MEK inhibitors, and a synergistic effect was observed when combined with pan-RAF inhibitor LY3001920 in a KRAS-mutant colorectal cancer model [63]. Here, MAP2K7 is linked to colorectal cancer.